<DOC>
	<DOCNO>NCT02772419</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety SC administration Benralizumab Placebo subject Eosinophilic Chronic Rhinosinusitis multicenter , randomize , double-blind , placebo-controlled study . The pharmacokinetics immunogenicity assess secondarily .</brief_summary>
	<brief_title>Study Benralizumab ( KHK4563 ) Patients With Eosinophilic Chronic Rhinosinusitis</brief_title>
	<detailed_description>Screening Period ( maximum 4 week ) , Randomized Treatment Period ( 24 week )</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<criteria>Patients 20 year 75 year age Eosinophilic chronic rhinosinusitis total score ≥ 11 accord diagnosis eosinophilic chronic rhinosinusitis enrollment A minimum bilateral nasal polyp score 3 maximum score 8 ( score least 1 maximum score 4 nostril ) screen enrollment Weight ≥ 40 kg screen A SinoNasal Outcome Test22 ( SNOT22 ) score &lt; 7 enrollment Any nasal surgery ( include polypectomy ) within 1 year prior date consent Hospitalization ≥ 24 hour treatment asthma exacerbation , within 12 week prior date consent Exposure commercially available ( e.g. , omalizumab ) investigational biologic agent within 16 week 5 halflives prior enrollment , whichever long Use systemic corticosteroid ( include oral corticosteroid ) corticosteroid nasal solution ( except spray ) within 4 week prior enrollment plan use medication doubleblind period Prior treatment benralizumab</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>